Track record · closed signal

Merck & Company Inc (MRK) — closed signal from May 1, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 30, 2026 — +15.3% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$109.42 – $112.87Entry zone — fair-value band

$112.56Published — price the day we called it

$121.82Target — the price the thesis aimed for

$135.05Peak — highest point inside the window, not a realized return

$129.79Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 55 days.

At window close

+15.3%

realized, from the publication price to the last close inside the window

Peak gain

+20%

peak, from the publication price — not a realized return

S&P 500, same window

+3.2%

SPY over the identical days, dividend-adjusted

Window close

$129.79

last close inside the window, ended July 30, 2026

Peak price

$135.05

peak on July 28, 2026 — not a realized return

Days to target

The thesis — published May 1, 2026

Predicted growth

+9%

over the measurement window

Target price

$121.82

the price the thesis aimed for

Entry zone

$109.42 – $112.87

the fair-value band we waited for

Price at publication

$112.56

published May 1, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is a lower-risk healthcare stock with clearer reasons to watch than many peers. Strong recent sales, rising Winrevair demand, higher guidance, and a rival's failed cancer test have improved sentiment. Downward price movement, worries about Keytruda's future, and uneven earnings limit conviction, but valuation and defensive traits make it worth monitoring.

Primary drivers

Winrevair sales are visibly gaining traction and creating near-term momentum
Higher guidance provides a firmer baseline for expected performance
A rival's failed cancer trial makes Merck's position relatively stronger
Defensive profile and attractive valuation help offset drug pipeline concerns

How it played out

MRK: target reached in 55 days

On May 1, Lyra published a short-term thesis for MRK at 112.56, expecting 9% growth. The thesis pointed to rising Winrevair demand, higher guidance, a rival's failed cancer test, and Merck's defensive profile and valuation. It also noted downward price movement, concern about Keytruda's future, and uneven earnings.

Within the window, MRK reached the 121.82 target in 55 days. It later peaked at 135.05 on July 28, a 20% gain from publication. The shares ended the window at 129.79, still above the target. The thesis played out and exceeded its stated price objective.

What happened during the window

On May 5, Merck completed its acquisition of Terns Pharmaceuticals. On July 16, Merck announced that the FDA had approved Lipfendra for adults with hypercholesterolemia.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals